Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Parkinson diseases (PD) is the second most common degenerative disease of the central nervous system. The development of early diagnostic biomarkers may help identify at-risk individuals and allow precocious interventions at the onset of disease and more precise monitoring of therapies that may slow disease progression.
Proof of concept studies indicated significant differences in pupil light response between PD patients and healthy controls. The feasibility of using pupillometry for assesment of PD will be examined.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Diagnostic Test: Pupillometry |
| |
| Parkinson patients | Diagnostic Test: Pupillometry |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pupil response to light stimuli | Diagnostic Test | Objective and accurate measurement of pupillary responses to light stimuli |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pupillometry | Pupil response to light stimuli | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Best corrected visual acuity | Visual Acuity | 1day |
| Color vision | Color vision by Farnsworth/Lanthon D-15 Test | 1 day |
Not provided
Inclusion Criteria:
General inclusion criteria
Patients' Inclusion Criteria:
Patients with clinical presentations of the neurodegenerative forms of parkinsonism (bradykinesia, extrapyramidal rigidity, tremor, postural instability and gait disturbance) including: idiopathic Parkinson disease (PD), Lewy body disease (LBD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD) and secondary parkinsonisms.
Control group- inclusion criteria
Normal eye examination
Best-corrected visual acuity (BCVA) of 20/20
Normal color vision test (Farnsworth/Lanthon D-15 Test)
No present ocular disease
No past ocular disease or surgery within last 6 months
No use of any topical or systemic medications that could adversely influence efferent pupil movements
Normal 24-2 Humphrey visual field and
Exclusion Criteria:
Not provided
Not provided
Not provided
One hundred Parkinson patients or patients with parkinsonism and 100 age-matched controls
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lori Gueta | Contact | 972527485888 | Lori.Gueta@sheba.health.gov.il |
| Name | Affiliation | Role |
|---|---|---|
| Sharon Hassin-Baer, Prof. | Sheba Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Goldschleger Eye Research Institute, Sheba Medical Center, | Recruiting | Tel Litwinsky | 52621 | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Humphrey 24-2 perimetry | Visual field will be assessed by Humphrey 24-2 perimetry | 1 day |
| Spcetral Domain Optical Coherence Tomography (SD-OCT) | Optic nerve and retinal structure will be assessed by SD-OCT | 1 day |
| visual evoked potential | Occipital cortex function will be assessed by visual evoked potential (VEP) | 1 day |
| Change from baseline Pupillometry at 1 year | Change from baseline in pupil response to light stimuli at 1 year | Single visit: 1 day, 1 year after baseline testing |
| Change from baseline best corrected visual acuity at 1 year | Change from baseline visual acuity at 1 year | Single visit: 1 day, 1 year after baseline testing |
| Change from baseline color vision at 1 year | Change from baseline color vision by Farnsworth/Lanthon D-15 at 1 year | Single visit: 1 day, 1 year after baseline testing |
| Change from baseline Humphrey 24-2 at 1 year | Change from baseline Humphrey 24-2 visual field at 1 year | Single visit: 1 day, 1 year after baseline testing |
| Change from baseline SD-OCT at 1 year | Change from baseline optic nerve and retinal structure by SD-OCTat 1 year | Single visit: 1 day, 1 year after baseline testing |
| Change from baseline visual evoked potential at 1 year | Change from baseline occipital cortex function by visual evoked potential testing to at 1 year | Single visit: 1 day, 1 year after baseline testing |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |